Ann: Trading Halt, page-40

So lets look at the $1B (assume it is AUD)

Relyvrio sales in 2023 were est at USD$380M <> AUD$587M


Relyvrio is ONLY available in the USA <> Monepantel seeking AU, EU, USA
Relyvrio had numerous customers drop off the treatment due to side effects <> Monepantel so far has very few adverse effects/well tolerated to date.
Relyvrio potential to extend life by average of 9 months (now not so true) <> Monepantel potentially double and more than than so the customer base per year increases (not passing away in 9 months, so on the treatment for much longer)

It may well be this statement that the ASX has taken as a please explain. We will see in time. I do think there is sufficient data to explain an AUD $1B potential annual sales but I can also see where the ASX is dubious too. Unlike us, I highly doubt they study the company fundamentals before demanding a please explain.

adreamer